Fibralign Corporation

Info

Contact Greg King
Title COO
Email gking@fibralignbio.com
Phone (415) 902-4721

Description

Fibralign’s first product BioBridge is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120M people and has no cure (World Health Org, other sources). The Company successfully completed a large animal study with Stanford (DoD funded) that validated BioBridge treated diseased lymphatic tissue. Fibralign is now preparing for 510(k) submission and a clinical study with Stanford. Fibralign has a strong IP position (11 patents, 14 pending) and a scalable manufacturing process for making this and other devices.

Company News

Fibralign and MedTech Innovator Featured in General Surgery News

/
DateFeb 13, 2017
The prizes valued at $150,000 awarded to the company that won the 2014 MedTech Innovator competition were nothing to sneeze at; but just as important, if not more so, were the support and exposure the startup received as participants of MTI’s accelerator program.

Fibralign beats 267 other startups at the 2014 MedTech Innovator competition

/
DateJul 14, 2014
The Biobridge is an implant that has been shown to be able to guide the growth of new lymph channels. This technology can be used as an adjunct to existing treatments for the condition to hopefully improve outcomes. Fibralign has benefited from grants from the DoD and NSF to support a large animal study and develop production tools for making its initial product.

Fibralign set to bring new device option for secondary lymphedema

/
DateJun 26, 2014
Fibralign's first product, BioBridge, is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120 million people and has no cure. The company successfully completed a large animal study that validated BioBridge-treated diseased lymphatic tissue. Fibralign is now preparing for 510(k) submission and a clinical study.